PNB-002

PNB-002 is a small molecule drug candidate developed by PNB Vesper Life Science. It is part of a pipeline of novel molecules synthesized for unmet medical needs, but there is no publicly available detailed information on its mechanism of action, molecular target, or specific disease indication as of June 2025. The company has focused on developing cost-effective drugs for serious diseases and has other related compounds (such as PNB-001 and PNB-028) that act as cholecystokinin receptor antagonists with anti-inflammatory and immunomodulatory properties; however, there is no direct evidence that PNB-002 shares these mechanisms or indications[3][5]. No clinical trial data or published studies specifically referencing the efficacy, safety profile, or development status of PNB-002 were found in the provided sources.